The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
News|Articles|March 5, 2019
SSB, Novasep to Develop Membrane Chromatography Systems
Author(s)Pharmaceutical Technology Editors
Sartorius Stedim Biotech (SSB) and Novasep will partner to develop systems for membrane chromatography using Novasep’s BioSC platform and SSB’s single-use technology.
Advertisement
On March 5, 2019, Sartorius Stedim Biotech (SSB), a biopharmaceutical supplier, and Novasep, a provider of molecule production and purification services, have entered into a collaboration agreement in which the companies will develop membrane chromatography systems using Novasep’s BioSC platform and SSB’s single-use technology.
According to SSB, systems that are currently on the market are designed for resins, but do not take full advantage of membrane chromatography capabilities. Optimally run membrane chromatography processes will provide an efficient alternative to batch and continuous resin-based chromatography, resulting in higher productivity, smaller scale operations, and increased robustness, SBB reports.
Novasep specializes in the design, manufacture and control of resin-based batch and continuous chromatography systems. The company’s BioSc platform is a low-pressure continuous chromatography solution for the purification of monoclonal antibodies, blood fractions and other biologics. The platform is adaptable, with operations from one column up to six columns in batch, parallel batch, continuous chromatography, or continuous process. Novasep states that the platform can easily switch from batch to continuous, has a reduction of resin and buffer by up to 75%, and increased productivity by two- to six-fold.
Source:
Advertisement
Related to this article
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
2
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
3
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
4
Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026
5